Inhibitors of KEAP1-Nrf2 protein-protein interaction

A compound of Formula (I) or a pharmaceutically acceptable salt thereof

• (I)
• wherein
• X is CH or N;
• Q is CH or N;
• M is CH;
• wherein
• when X is N, Q is CH;
• when Q is N, X is CH;
• R15 is CH3 or Cl;
• R13 is H, F or C1-C4alkyl;
• R14 is H, F or C1-C4alkyl;
• HetA is selected from the group consisting of
• wherein
• R1 is selected from the group consisting of C3-C4cycloalkyl, C1-C4alkyl and C1-C4alkyl monosubstituted with cyclopropyl or cyclobutyl;
• R2 is selected from the group consisting of H, C1-C4alkyl and C1-C4perhaloalkyl;
• R3 is H or C1-C4alkyl;
• R4 is selected from the group consisting of C1-C4alkyl, C1-C4perhaloalkyl and C3-C4cycloalkyl;
• R7 is H or C1-C4alkyl;
• R8 is C1-C4alkyl;
• R9 is C1-C4alkyl;
• R10 is selected from the group consisting of H, —OC3-C4cycloalkyl and —OC1-C4perhaloalkyl;
• HetB is selected from the group consisting of
• wherein
• Z is selected from the group consisting of O, CH2, NH and N(CH3);
• T is CH or N;
• Y is CH or N;
• W is CH or N;
• V is O or N(CH3);
• R16 is H or F;
• R17 is H or F;
• n is 0, 1 or 2;
• R18 is selected from the group consisting of H, —CN, halo, C(O)NH2, C1-C4alkyl and C1-C4perhaloalkyl;
• R19 is selected from the group consisting of H;
• CN;
• halo;
• C(O)NH2;
• N(R38)C1-C6alkyl;
• C1-C4alkyl;
• C1-C4perhaloalkyl;
• OC1-C6alkyl;
• OC1-C6alkyl substituted with one or two substituents selected from the group consisting of —OH, —OCH3, —O(CH2)3OH, —N(R36)R37, C1-C4alkyl,
• —N(R38)C1-C6alkyl substituted with one or two substituents selected from the group consisting of OH, —OCH3, —N(R36)R37, C1-C4alkyl,
• and
• C1-C4alkyl monosubstituted with a substituent selected from the group consisting of —C(O)NHCH2CH2OH, —C(O)NHCH2CH2OCH2CH2NH2, C(O)NH2 and OH;
• R20 is H or C1-C4alkyl;
• R21 is selected from the group consisting of H, —CN, halo, C1-C4alkyl and C1-C4perhaloalkyl;
• R22 and R23 are taken together with the carbon to which they are attached to form
• (a) the moiety
• wherein R is selected from the group consisting of CH2, NR38 and O, m is 0 or 1, and p is 0 or 1;
• or
• (b) the moiety
• R22′ is selected from the group consisting of H, C1-C4alkyl and C3-C4cycloalkyl, and
• R23′ is selected from the group consisting of H, C1-C4alkyl and C3-C4cycloalkyl;
• R24 is selected from the group consisting of H;
• CN;
• halo;
• C(O)NH2;
• C(O)(NH)C3-C4cycloalkyl;
• N(R38)C1-C6alkyl;
• C1-C4alkyl;
• C1-C4perhaloalkyl;
• OC1-C6alkyl;
• OC1-C6alkyl substituted with one or two substituents selected from the group consisting of —OH, —OCH3, —O(CH2)3OH, —N(R36)R37, C1-C4alkyl;
• N(R38)C1-C6alkyl substituted with one or two substituents selected from the group consisting of OH, —OCH3, —N(R36)R37, C1-C4alkyl,
• and
• C1-C4alkyl monosubstituted with a substituent selected from the group consisting of —C(O)NHCH2CH2OH, —C(O)NHCH2CH2OCH2CH2NH2, C(O)NH2 and OH;
• R25 is selected from the group consisting of H;
• CN;
• halo;
• C(O)NH2;
• N(R38)C1-C6alkyl;
• C1-C4alkyl;
• C1-C4perhaloalkyl;
• OC1-C6alkyl;
• OC1-C6alkyl substituted with one or two substituents selected from the group consisting of —OH, —OCH3, —O(CH2)3OH, —N(R36)R37, C1-C4alkyl,
• —N(R38)C1-C6alkyl substituted with one or two substituents selected from the group consisting of —OH, —OCH3, —N(R36)R37, C1-C4alkyl,
• and
• C1-C4alkyl monosubstituted with a substituent selected from the group consisting of —C(O)NHCH2CH2OH, —C(O)NHCH2CH2OCH2CH2NH2, C(O)NH2 and OH;
• R26 is selected from the group consisting of H, —CN, halo, C1-C4alkyl and C1-C4perhaloalkyl;
• R27 is H or C1-C4alkyl;
• R36 and R37 are independently selected from the group consisting of H and C1-C4alkyl;
• R38 is H or C1-C4alkyl;
• provided that when HetA is
• then HetB is not